Shots: Evotec to receive research funding & is eligible for milestones. Evotec will support Rappta’s program of developing small molecule activators of the enzyme PP2A The collaboration leverages Evotec’s integrated platform for drug discovery and development and its oncology expertise coupled with state-of-the-art technologies PP2A is a serine/threonine phosphatase that functions as a tumor suppressor […]Read More
Shots: The P-I dose-escalation study will assess the safety, tolerability, and preliminary efficacy of DS-1055 in adult patients with r/r advanced or metastatic head and neck, gastric and esophageal cancers, and other tumor types The focus of the study is to determine the maximum tolerated dose and recommended dose of DS-1055 for further study and […]Read More
Shots: The US FDA has granted 510 (k) clearance to HealthMammo for boosting early detection of breast cancer in mammograms The tool utilizes the AI to prioritize and identify suspicious mammograms and is automatically sent to Zebra’s platform, where it gets processed and analyzed for suspected breast lesions. The HealthMammo product then returns its result […]Read More
Shots: Daichii Sankyo to receive $1B as upfront of which $350M is due upon execution, $325M after 12mos. and $325M after 24 mos., ~$5B as contingent payment including $1B as regulatory milestones, and $4B as commercial milestones, making a total deal value up to ~6B The companies will jointly develop and commercialize DS-1062 globally and […]Read More
Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected […]Read More
Shots: NCCN and Pfizer have issued an open RFP that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology The RFP supports approaches to improve the processes related to biosimilar adoption in oncology. Letters of Intent are welcome from academic or community centers, patient advocacy groups and […]Read More
Shots: Sanofi and MD Anderson collaborated for 5yrs. to ramp up the development of investigational treatments, including targeted and immune-therapies for oncology patients. The alliance will support investigations into additional indications and combinations for studies already in the clinic The collaboration will integrate MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to […]Read More
Shots: Regeneron to receive $30M up front and ~$160M as regulatory and commercial milestones. Zai Lab will lead the global development costs of REGN1979 and will receive exclusive rights to develop and commercialize REGN1979 to treat oncology in China, Hong Kong, Taiwan and Macau The alliance will support the global clinical development of REGN1979, initiating […]Read More
Shots: Atreca to receive up front and retain rights to develop Abs included in the collaboration with Merck while Merck will get a right-of-first negotiation, if Atreca out-licenses its one or more Abs therapies Following target identification, both the companies have the right to advance therapeutic candidates against the targets identified under the collaboration in […]Read More
Shots: Roche signs a 15yrs. non-exclusive agreement with Illumina, allowing patients to access next-generation sequencing (NGS) based testing in oncology Roche to get right to develop & commercialize AVENIO IVD tests for both tissue and blood to be used on Illumina’s NextSeq 550Dx System while Illumina will continue to commercialize its NextSeq 550Dx Systems and […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
